Merck reveals FDA drug rejections, DOJ probe in SEC filing
This article was originally published in Scrip
Executive Summary
Merck made several disclosures this week in a filing with the US Securities & Exchange Commission, including that the US FDA rejected two of its drugs and the Department of Justice (DOJ) issued a subpoena about the Whitehouse Station, New Jersey pharma's marketing and selling activities related to two other medicines.